STOCKHOLM, July 22, 2022 /PRNewswire/ — Continued progress during Q2 2022 ” The second quarter of 2022 provided the latest data point to confirm IRRAS’ progress toward becoming a leader in neurocritical care. Q2 represented the 8th consecutive quarter of revenue growth for our company, and our revenue of MSEK 9.7 (5.1) […]
Other News
Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia’s new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on […]
IRHYTHM GAINS FDA CLEARANCE FOR ITS CLINICALLY INTEGRATED ZEUS SYSTEM
Developed in partnership with Verily, the Zio® Watch and the ZEUS System combine to create a clinical grade watch to detect and characterize AFib and integrate with clinician’s workflow SAN FRANCISCO, July 22, 2022 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, […]
MemorialCare Long Beach Medical Center is Nationally Recognized with American Heart Association/American Stroke Association…
MemorialCare Long Beach Medical Center is Nationally Recognized with American Heart Association/American Stroke Association’s Gold Plus Awards for Heart Failure, Stroke Care, and Diabetes LONG BEACH, Calif., July 21, 2022 /PRNewswire/ — MemorialCare Long Beach Medical Center has received the American Heart Association’s Get With The Guidelines® – Heart Failure Gold Plus Quality Achievement […]
Acutus Medical Announces CEO Appointment and Preliminary Second Quarter Revenue Results
CARLSBAD, Calif., July 21, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced that David Roman has been appointed President and Chief Executive Officer, and member of the Board […]
RapidAI Receives FDA Clearance for Rapid Hyperdensity
The new solution allows for quick identification of hyperdense volumes to improve hemorrhage management SAN MATEO, Calif.–(BUSINESS WIRE)–RapidAI, the global leader in neurovascular and vascular AI-enhanced clinical decision support and patient workflow, today announced it has received FDA clearance for Rapid Hyperdensity, the newest addition to the RapidAI platform. The tool empowers […]
SANUWAVE® Business Update – June 2022
Estimated June Revenue Increase of 75% Year Over Year Sales Funnel Increases 9% and System Trials Increases 5% Month Over Month SUWANEE, GA, July 21, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — On July 14, 2022, SANUWAVE Health, Inc. (OTC: PINK: SNWV), a leading provider of next-generation wound care products, provided an […]
BioSig Announces Physician-Initiated Research Protocol at The Kansas City Heart Rhythm Institute
Led by Dhanunjaya DJ Lakkireddy, MD., the study will investigate expanded applications for the signals acquired by BioSig’s PURE EP(T.M.) System Westport, CT, July 21, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal […]
dal-GenE Phase 3 Cardiovascular Precision Medicine Outcomes Trial Results Published in European Heart Journal
Trial was negatively impacted by the COVID-19 pandemic and did not meet the primary endpoint. However, the results validate the interaction between dalcetrapib treatment and AA genotype at variant rs1967309 in the ADCY9 gene. LONDON and MONTREAL, July 21, 2022 (GLOBE NEWSWIRE) — DalCor Pharmaceuticals announced the results of the […]
Verve Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
CAMBRIDGE, Mass., July 21, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, Inc. (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of its upsized underwritten public offering of 8,333,334 shares of its common stock at a public […]